| Project Number | pCODR 10116 |
|---|---|
| Brand Name | Adcetris |
| Generic Name | Brentuximab Vedotin |
| Strength | 50 mg |
| Tumour Type | Lymphoma and Myeloma |
| Indication | Hodgkin’s Lymphoma at high risk of relapse or progression post-ASCT |
| Funding Request | For post-ASCT consolidation treatment of patients with HL at high risk of relapse or progression. High risk of relapse post-ASCT is defined according to status following frontline therapy: refractory, relapse within 12 months, or relapse at greater or equal to 12 months with extranodal disease |
| Review Status | Pending |
| Pre Noc Submission | Yes |
| NOC Date | |
| Manufacturer | Seattle Genetics, Inc. |
| Submitter | Seattle Genetics, Inc. |
| Submission Date (Target Date) | August 10, 2017 |
| Submission Type | Resubmission |
| Prioritization Requested | |
| Stakeholder Input Deadline (target date based on target submission date) ‡ | August 24, 2017 |
| Check-point meeting (target date) | |
| pERC Meeting (target date) | |
| Initial Recommendation Issued (target date) | |
| Feedback Deadline (target date) ‡ | |
| pERC Reconsideration Meeting (target date) | |
| Final Recommendation Issued (target date) | |
| Notification to Implement Issued |
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.